Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Drug Regulator Takes New Step In Adding To Approval Procedure

This article was originally published in PharmAsia News

Executive Summary

The Drug Controller General of India has selected six laboratories it intends to rely on to test drugs before they are allowed on the Indian market. The DCGI said it is considering the system for making the review process work, including a public-private partnership arrangement. The agency is considering adding the testing procedure instead of relying solely on clinical trial data submitted by drug makers as an additional guarantee of quality. The six government labs have been identified as capable of providing the testing envisioned. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel